Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,696 questions · 3,815 findings · 855 reviews

No studies found 573 · 15%GRADE not reported 374 · 9.8%Very low 993 · 26%Low 1,062 · 27.8%Moderate 614 · 16.1%High 199 · 5.2%

Summary of findings table ‐ Convalescent plasma vs standard plasma

Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes clinical worsening: need for invasive mechanical ventilation, or… compared with standard plasma (very low certainty).

1 finding from 1 review

Tranexamic acid vs placebo

Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Tranexamic acid changes risk of reoperation or repeat procedure for bleeding within 7 days compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings: Fibrin sealant vs usual care

All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).

1 finding from 1 review

Summary of findings: Fibrin sealant vs usual care

Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery

It is very uncertain whether summary of findings: Fibrin sealant changes risk of reoperation or repeat procedure for bleeding within 7 days compared with usual care (very low certainty).

1 finding from 1 review

Intervention not reported

mg/day LDL cholesterol · participants with normal or abnormal lipid profiles

The intervention showed no clear difference in mg/day LDL cholesterol (high certainty).

1 finding from 1 review

Intervention not reported

mg/day LDL cholesterol · participants with normal or abnormal lipid profiles

The intervention showed no clear difference in mg/day LDL cholesterol (moderate certainty).

1 finding from 1 review

Intervention not reported

mg/day LDL cholesterol · participants with normal or abnormal lipid profiles

The intervention showed no clear difference in mg/day LDL cholesterol (moderate certainty).

1 finding from 1 review

Intervention not reported

mg/day LDL cholesterol · participants with normal or abnormal lipid profiles

The intervention showed no clear difference in mg/day LDL cholesterol (high certainty).

1 finding from 1 review

Intervention not reported

Pravastatin 10 to 80 mg/day (6 to 156 weeks) · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Single foetal haemoglobin inducer at any dose or duration vs another dose or dose regimen of the same foetal haemoglobin inducer

Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer

Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Progestogens vs GnRH antagonists

Total oocytes ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review